Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAY NASDAQ:CTSO NASDAQ:SKIN NASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsway$11.47-1.8%$11.73$5.98▼$13.65$220.72M1.4246,583 shs18,876 shsCTSOCytosorbents$0.87+2.3%$1.04$0.71▼$1.61$54.42M1.1964,449 shs4.61 million shsSKINBeauty Health$1.53-0.6%$1.77$0.78▼$2.38$194.03M1.2665,360 shs540,357 shsSMTISanara MedTech$24.160.0%$28.16$23.53▼$39.08$214.82M1.2649,393 shs51,420 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsway-1.80%-2.22%-10.39%+27.16%+58.43%CTSOCytosorbents+2.26%-7.88%-13.08%-7.53%-27.57%SKINBeauty Health-0.65%-14.53%-27.49%+34.21%-17.30%SMTISanara MedTech-0.04%-5.37%-19.31%-26.54%-24.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsway3.2569 of 5 stars2.55.00.00.03.90.81.9CTSOCytosorbents1.1869 of 5 stars3.32.00.00.00.00.00.6SKINBeauty Health1.4975 of 5 stars2.80.00.00.02.73.30.0SMTISanara MedTech1.599 of 5 stars3.51.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsway 3.00Buy$14.2524.24% UpsideCTSOCytosorbents 2.50Moderate Buy$5.50532.77% UpsideSKINBeauty Health 1.67Reduce$2.0836.17% UpsideSMTISanara MedTech 3.00Buy$49.50104.88% UpsideCurrent Analyst Ratings BreakdownLatest CTSO, SMTI, SKIN, and BWAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025SKINBeauty HealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.00 ➝ $4.007/21/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/9/2025BWAYBrainswayHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/15/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $53.005/5/2025SKINBeauty HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.255/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsway$41.02M5.28$0.24 per share46.84$3.31 per share3.47CTSOCytosorbents$35.33M1.54N/AN/A$0.20 per share4.35SKINBeauty Health$334.30M0.58$0.06 per share24.35$0.41 per share3.73SMTISanara MedTech$86.67M2.48N/AN/A$4.45 per share5.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsway$2.92M$0.2057.3571.69N/A9.01%7.35%4.72%8/5/2025 (Estimated)CTSOCytosorbents-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/7/2025 (Estimated)SKINBeauty Health-$29.10M-$0.41N/AN/AN/A-11.94%-67.91%-5.56%8/7/2025 (Estimated)SMTISanara MedTech-$9.66M-$1.34N/AN/AN/A-12.48%-29.22%-13.20%8/13/2025 (Estimated)Latest CTSO, SMTI, SKIN, and BWAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BWAYBrainsway$0.07N/AN/AN/A$12.34 millionN/A8/13/2025Q2 2025SMTISanara MedTech-$0.33N/AN/AN/A$25.15 millionN/A8/7/2025Q2 2025CTSOCytosorbents-$0.07N/AN/AN/A$9.79 millionN/A8/7/2025Q2 2025SKINBeauty Health-$0.06N/AN/AN/A$74.67 millionN/A5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/14/2025Q1 2025SMTISanara MedTech-$0.31-$0.41-$0.10-$0.41$23.48 million$23.43 million5/13/2025Q1 2025BWAYBrainsway$0.02$0.04+$0.02$0.04$11.45 million$11.54 million5/8/2025Q1 2025SKINBeauty Health-$0.13-$0.08+$0.05-$0.08$63.88 million$69.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainswayN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainswayN/A5.034.75CTSOCytosorbents0.982.612.30SKINBeauty Health12.017.476.43SMTISanara MedTech1.182.772.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsway30.11%CTSOCytosorbents32.87%SKINBeauty Health93.26%SMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipBWAYBrainsway19.00%CTSOCytosorbents7.30%SKINBeauty Health41.00%SMTISanara MedTech42.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsway12018.90 million15.31 millionNot OptionableCTSOCytosorbents22062.61 million58.04 millionOptionableSKINBeauty Health1,030125.99 million74.34 millionOptionableSMTISanara MedTech608.89 million5.10 millionNot OptionableCTSO, SMTI, SKIN, and BWAY HeadlinesRecent News About These CompaniesSanara MedTech (NASDAQ:SMTI) Stock Price Down 1.5% - Here's WhyJuly 18, 2025 | marketbeat.comSanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025July 15, 2025 | globenewswire.comSanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot ProgramJuly 14, 2025 | globenewswire.comSanara MedTech: Pursuing Rapid Expansion While Debt Levels ClimbJune 9, 2025 | seekingalpha.comSanara MedTech Shares Down, Investors Sought For Pilot ProgramMay 15, 2025 | marketwatch.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (SMTI) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comSanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) | SMTI Stock NewsMay 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | investing.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | globenewswire.comWith 31% ownership, Sanara MedTech Inc. (NASDAQ:SMTI) insiders have a lot riding on the company's futureMay 6, 2025 | uk.finance.yahoo.comSanara MedTech Inc. to Report Q1 2025 Financial Results on May 14, 2025April 23, 2025 | quiverquant.comQSanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025April 23, 2025 | globenewswire.comSanara MedTech to Present at Investor ShowcaseApril 22, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTSO, SMTI, SKIN, and BWAY Company DescriptionsBrainsway NASDAQ:BWAY$11.47 -0.21 (-1.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.95 +0.48 (+4.22%) As of 08/1/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Cytosorbents NASDAQ:CTSO$0.87 +0.02 (+2.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.84 -0.03 (-3.47%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Beauty Health NASDAQ:SKIN$1.53 -0.01 (-0.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.54 +0.00 (+0.33%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.Sanara MedTech NASDAQ:SMTI$24.16 -0.01 (-0.04%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$25.36 +1.20 (+4.98%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
